NASDAQ · ELVN
Enliven Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ELVN: Nov 11, 2026
Enliven Therapeutics, Inc. Common Stock is estimated to report earnings on 11/11/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.48. The reported EPS for the same quarter last year was $-0.32.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.48 | $-0.41 | $-0.54 | 5 |
| Dec 2026 | $-0.56 | $-0.46 | $-0.69 | 5 |
| Mar 2027 | $-0.52 | $-0.48 | $-0.59 | 4 |
| Jun 2027 | $-0.56 | $-0.50 | $-0.61 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · BNK Invest- RTTNews · Oct 15, 3:02 AM EDTEnliven Appoints Former Antiva CEO Kristine Ball To Board As Relcobatinib Nears Phase 3 Launch(RTTNews) – Enliven Therapeutics, Inc. (ELVN), a clinical-stage biopharmaceutical company focused on small molecule therapeutics, announced the appointment of Kristine Ball to its Board of Directors, effective immediately. Kristine Ball brings more than 20 years of executive ex
- RTTNews · Oct 7, 2:30 AM EDTEnliven Gets FDA Alignment For Phase 3 Relcobatinib Trial In Blood Cancer(RTTNews) – Enliven Therapeutics, Inc. (ELVN), a clinical-stage biopharmaceutical company developing small-molecule therapies, reported it has reached alignment with the U.S. FDA on the final design of ENABLE-2 trial of Relcobatinib in adults with previously treated chronic myelo
- RTTNews · Aug 2, 6:54 AM EDT5 Biotech Stocks That Delivered Big Gains – Key Catalysts Ahead For QURE, CDNA, ADPT, ELVN & AMLX(RTTNews) – As Warren Buffett once said, "If you find three wonderful businesses in your life, you'll get very rich." His message underscores the importance of identifying a handful of exceptional companies capable of delivering sustained long-term value, rather than chasing nume
- RTTNews · Jul 17, 5:13 AM EDTBiotech Stocks At 52-Week Highs- CDNA, IART, AGL, BVS, ELVN(RTTNews) – The following biotech stocks reached 52-week highs on July 16, 2026, resulting due to anticipated quarterly report releases or an upcoming conference participation.
- The Motley Fool · Jun 27, 3:56 PM EDTWhat to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%A director of Enliven Therapeutics reported selling 10,000 shares in open-market transactions on June 5, 2026, for a total value of $345,000.
- The Motley Fool · Jun 27, 12:23 PM EDTWhat to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% RallyOrbimed Advisors reported selling 860,123 shares of ELVN on June 22, 2026, generating a transaction value of approximately $39.0 million at an average price of $45.36 per share.
- The Motley Fool · Jun 24, 3:32 PM EDTMedical Hedge Fund Sells 281,000 Shares of Enliven Theapeutics. Is it Time to Sell ELVN?Medical-focused hedge fund Orbimed Advisors sold 281,408 shares on June 15, 2026, for nearly $13 million at an average price of $45.02 per share.
- RTTNews · Jun 14, 10:02 PM EDTTop Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch(RTTNews) – Among Friday's notable biotech movers were TherapeuticsMD, which is evaluating a strategic review process; Sensei Biotherapeutics, supported by optimism surrounding a key clinical catalyst expected in the second half of 2026; and Alumis, which is advancing its lead th
- RTTNews · Jun 11, 11:50 AM EDTEnliven Reports Updated Positive Results From Phase 1 Trial Of ELVN-001 In Treating CML(RTTNews) – Enliven Therapeutics, Inc. (ELVN), reported on Thursday an updated positive result from the Phase 1 ENABLE trial of ELVN-001 in patients who were previously treated for Chronic Myeloid Leukemia (CML).
- The Motley Fool · Jun 1, 5:45 PM EDTEnliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.Chief Medical Officer Helen Collins sold 5,000 shares of Common Stock for a total of ~$199,000 on May 18, 2026, at an average price of around $39.79 per share.
- BNK Invest · May 29, 3:32 PM EDTNoteworthy Friday Option Activity: ELVN, AAPL, COINLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Enliven Therapeutics Inc (Symbol: ELVN), where a total volume of 16,050 contracts has been traded thus far today, a contract volume which is representative of ap
- The Motley Fool · May 13, 5:06 PM EDTWhy This Biotech Fund Added $7 Million to an Oncology Stock Up 120%Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Enliven Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.